ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Non-Small-Cell Lung Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Berlin, BE, DEU:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Berlin, Germany and 24 other locations

therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 3

Immunocore
Immunocore

Berlin, Germany and 65 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Active, not recruiting
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Berlin, Germany and 110 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Berlin, Germany and 227 other locations

At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observat...

Enrolling
Uveal Melanoma
Drug: Tebentafusp

Phase 3

European Organisation for Research and Treatment of Cancer (EORTC)

Berlin, Germany and 3 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Berlin, Germany and 55 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Berlin, Germany and 65 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Biological: Durvalumab
Drug: Ceralasertib

Phase 2

AstraZeneca
AstraZeneca

Berlin, Germany and 65 other locations

with previously untreated unresectable or metastatic (advanced) melanoma.Patients will be stratified on the basis of the following factors; ...

Active, not recruiting
Unresectable Melanoma
Metastatic Melanoma
Drug: Pembrolizumab
Drug: IO102-IO103

Phase 3

IO Biotech

Berlin, Germany and 111 other locations

not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 189 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems